Nebivolol: Does the Key Lie in ?3 Agonism?

Hernán Cohen Arazi and Miguel Gonzalez

Department of Cardiology and Cardiovascular Surgery, Centro Médico Pilares, Buenos Aires Argentina CEMIC, Buenos Aires Argentina
Department of Cardiovascular Surgery, Sanatorio Finochietto, Buenos Aires, Argentina

^*Correspondance to: Hern�n Cohen Arazi 

 PDF  Full Text DOI: 10.25107/2474-1647.1660

Abstract

Beta-blockers are drugs indicated in the treatment of multiple cardiovascular pathologies. The review highlights the mechanisms of action of Nebivolol and its particular potential effect on β3 receptors that increases nitric oxide that may mark very significant differences, which are traduced to benefits in clinical results. Nebivolol has an special place in the treatment of adrenergic hypertension associated with tachycardia and emotional stress, more frequently in young individuals, and may be considered adequate even in patients with glucose and lipid metabolism disorders due to its pleiotropic effect. In patients with heart failure, Nebivolol showed effectiveness and safety in patients over 75 years old. Nebivolol showed a reduction of cardiomyocyte apoptosis and improvement of contractile function through a mechanism related to β3 receptor agonism after an acute coronary syndrome. Because of all these actions Nebivolol should be considered not only a third-generation Beta-blocker.

Keywords

Cite the article

Arazi HC, Gonzalez M. Nebivolol: Does the Key Lie in ?3 Agonism? Clin Surg. 2017; 2: 1660.